ArticleAddiction (Abingdon, England)2022
The estimated impact of state-level support for expanded delivery of substance use disorder treatment during the COVID-19 pandemic.
Article in Addiction (Abingdon, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Spatial Patterns of Opioid Overdose Mortality Risk Across Urban, Transitional, and Rural Communities Using Satellite-Derived and Socioeconomic Indicators.Journal of urban health : bulletin of the New York Academy of Medicine · 2026Article
- Narrative Review of Opioid Use Disorder Treatment Changes During the COVID-19 Pandemic and Their Impact on American Indian/Alaska Native Communities.Nursing open · 2026Review
- The Digital Divide and Tele-MOUD: A Qualitative Study of Opioid Community Coalition Perspectives During COVID-19.Telemedicine journal and e-health : the official journal of the American Telemedicine Association · 2025Article
- "Yeah, this is not going to work for me"-The impact of federal policy restrictions on methadone continuation upon release from jail or prison.Journal of substance use and addiction treatment · 2025Article
- Provider perspectives on the impact of COVID-19 on treatment of substance use and opioid use disorders among American Indian and Alaska Native adults.Frontiers in public health · 2024Article
- Mortality, incarceration and cost implications of fentanyl felonization laws: A modeling study.The International journal on drug policy · 2023Article
- Changes to methadone maintenance therapy in the United States, Canada, and Australia during the COVID-19 pandemic: A narrative review.Journal of substance use and addiction treatment · 2023Review
- A qualitative exploration of barriers and facilitators to drug treatment services among people who inject drugs in west Virginia.Harm reduction journal · 2023Article
- A cyclic behavioral modeling aspect to understand the effects of vaccination and treatment on epidemic transmission dynamics.Scientific reports · 2023Article
- "There's absolutely no downside to this, I mean, except community opposition:" A qualitative study of the acceptability of vending machines for harm reduction.Harm reduction journal · 2023Article
- Article
- Barriers to Assessing and Treating Trauma in Primary Care and Opportunities for Improvement: Perspectives from Prescribers of Medications for Opioid Use Disorder.Substance use & misuse · 2023Article
- The impact of COVID-19 on the treatment of opioid use disorder in carceral facilities: a cross-sectional study.Health & justice · 2022Article
- Opioid overdose decedent characteristics during COVID-19.Annals of medicine · 2022Article
- Racial Discrimination, Mental Health and Behavioral Health During the COVID-19 Pandemic: a National Survey in the United States.Journal of general internal medicine · 2022Article
- Response to McIlveen et al.: Collaboration and transparency are necessary to effectively estimate substance use disorder treatment need.Addiction (Abingdon, England) · 2022Article
- Changes in Racial/Ethnic Disparities in Opioid-Related Outcomes in Urban Areas during the COVID-19 Pandemic: A Rapid Review of the Literature.International journal of environmental research and public health · 2022Review
- Barriers and poor telephone counseling experiences among patients receiving medication for opioid use disorders.Patient education and counseling · 2022Article
- A cross-sectional study of factors associated with COVID-19 testing among people who inject drugs: missed opportunities for reaching those most at risk.BMC public health · 2022Article
- Factors Associated with COVID-19 Testing among People who Inject Drugs: Missed Opportunities for Reaching those Most at Risk.medRxiv : the preprint server for health sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
BACKGROUND AND
aimsTo prevent COVID-19 transmission, some United States (US) federal regulations on substance use disorder (SUD) treatment were suspended in March 2020. This study aimed to quantify the extent of state-level policy uptake and the potential number of people with SUD affected by these policy changes across the US, as well as to assess if policy uptake correlated with rates of people with SUD already in treatment or needing treatment.
designCross-sectional analysis of policies implemented as of April 13, 2020. SETTING AND
participantsA total of 50 US states and the District of Columbia MEASUREMENTS: State-level implementation of: oral schedule II controlled substances emergency prescription, extended take-home doses for medication for opioid use disorders (MOUD), home-delivery of take-home medications, telemedicine for schedule II-IV prescriptions, telemedicine for buprenorphine prescribing initiation, and waiver of out-of-state Drug Enforcement Administration (DEA) registration. Rates per 100 000 population of: adults in treatment for SUD, MOUD treatment at facilities with opioid treatment programs, SUD based on Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV criteria, and needing, but not receiving treatment.
findingsHalf of the states (n = 24) enacted no policies, leaving ~460 955 people in treatment and 114 370 people on MOUD pre-pandemic uncovered by any policy expansion. Only telemedicine for buprenorphine initiation was marginally associated with pre-pandemic rate of SUD treatment (OR = 1.003, 95% CI = [1.001, 1.006]) and rate of MOUD therapy (OR = 1.006, 95% CI = [1.002, 1.011]) in univariable analysis, but these associations were no longer significant when controlling for state-level demographics. No policies were associated with state-wide SUD prevalence or rate of unmet treatment need (P > 0.05).
conclusionsTwenty-four United States states did not implement at least one federal policy for substance use disorder treatment expansion as of April 2020, leaving approximately half a million people in treatment pre-pandemic potentially without access to treatment or risking exposure to COVID-19 to continue in-person therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.